cmAngio® vs vascuCAP
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A focuses on detecting Breast Arterial Calcifications (BAC) from mammograms to provide early insights into cardiovascular risk, primarily leveraging existing breast imaging data. Tool B, conversely, analyzes CT angiograms to quantify arterial plaque composition and characterize specific plaque types for detailed cardiovascular risk stratification and treatment planning. While both contribute to cardiovascular risk assessment, they utilize distinct imaging modalities and target different aspects of disease manifestation, making them suitable for different clinical contexts and patient populations.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
cmAngiou00ae by CureMetrix analyzes Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams to detect Breast Arterial Calcifications (BAC). In contrast, vascuCAP (now ElucidVivo/PlaqueIQ) by Elucid Bioimaging analyzes CT angiography to quantify plaque composition and assess cardiovascular risk.
cmAngiou00ae provides AI-based detection and visualization of Breast Arterial Calcifications (BAC) on a scorecard, offering insights into cardiovascular health and aiding early risk assessment, particularly for women. vascuCAP offers histologically-validated quantification and characterization of plaque components, including lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage, along with risk stratification for stroke and heart attack.
cmAngiou00ae focuses on identifying Breast Arterial Calcifications (BAC) from existing mammograms, which can serve as an early indicator of cardiovascular health without requiring additional radiation or procedures. vascuCAP analyzes CT angiograms to provide detailed quantification and characterization of atherosclerotic plaque, enabling risk stratification for stroke and heart attack and supporting personalized treatment decisions.
cmAngiou00ae is compatible with any DICOM-compliant viewer and is designed for quick and easy installation, typically in less than an hour. vascuCAP features DICOM integration and PACS/EMR interoperability to streamline its use within clinical settings.
cmAngiou00ae is relevant for Cardiology, Obstetrics & Gynecology, and Radiology, focusing on leveraging mammography for women's cardiovascular health insights. vascuCAP is designed for Cardiology, Radiology, and Vascular Surgery, providing detailed plaque analysis from CT angiography to inform treatment decisions.